These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1699284

  • 1. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
    Hochster H, Cassileth P.
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
    [Abstract] [Full Text] [Related]

  • 2. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
    Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R.
    J Clin Oncol; 2006 Apr 01; 24(10):1590-6. PubMed ID: 16575010
    [Abstract] [Full Text] [Related]

  • 3. [The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
    Gershanovich ML, Zaritskiĭ AIu, Medvedeva NV, Abdulkadyrov KM, Samuskevich IG, Beresneva IA.
    Vopr Onkol; 1998 Apr 01; 44(6):696-700. PubMed ID: 10087967
    [Abstract] [Full Text] [Related]

  • 4. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
    Keating MJ.
    Semin Oncol; 1990 Oct 01; 17(5 Suppl 8):49-62. PubMed ID: 1699283
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
    Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T.
    J Clin Oncol; 2006 Jan 01; 24(1):174-80. PubMed ID: 16330664
    [Abstract] [Full Text] [Related]

  • 6. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ, Yang JM, Song XM, Chen L, Zhang WP, Ni X, Xu XQ, Wang JM.
    Zhonghua Zhong Liu Za Zhi; 2007 Sep 01; 29(9):710-2. PubMed ID: 18246806
    [Abstract] [Full Text] [Related]

  • 7. New initiatives with fludarabine monophosphate in hematologic malignancies.
    Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V.
    Semin Oncol; 1993 Oct 01; 20(5 Suppl 7):13-20. PubMed ID: 7694371
    [Abstract] [Full Text] [Related]

  • 8. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
    Hiddemann W, Unterhalt M, Pott C, Wörmann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert J.
    Semin Oncol; 1993 Oct 01; 20(5 Suppl 7):28-31. PubMed ID: 8235693
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
    Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hiddemann W, Radford JA, Norton AJ, Tollerfield SM, Wilson MP, Lister TA.
    J Clin Oncol; 1999 Feb 01; 17(2):546-53. PubMed ID: 10080598
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
    Rossi JF, van Hoof A, de Boeck K, Johnson SA, Bron D, Foussard C, Lister TA, Berthou C, Kramer MH, Littlewood TJ, Marcus RE, Deconinck E, Montillo M, Guibon O, Tollerfield SM.
    J Clin Oncol; 2004 Apr 01; 22(7):1260-7. PubMed ID: 15051774
    [Abstract] [Full Text] [Related]

  • 11. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
    Grever M, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S, Malspeis L.
    Semin Oncol; 1990 Oct 01; 17(5 Suppl 8):39-48. PubMed ID: 1699282
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
    Santini G, Contu A, Porcellini A, Chisesi T, Coser P, Congiu AM, Morandi S, Manna A, Schintu GM, Quaini R.
    Haematologica; 1991 Oct 01; 76(6):485-90. PubMed ID: 1820985
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
    Hochster HS, Kim KM, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ.
    J Clin Oncol; 1992 Jan 01; 10(1):28-32. PubMed ID: 1727921
    [Abstract] [Full Text] [Related]

  • 20. Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
    Binet JL.
    Nouv Rev Fr Hematol (1978); 1993 Feb 01; 35(1):5-7. PubMed ID: 7685518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.